Journal
FUTURE MICROBIOLOGY
Volume 6, Issue 1, Pages 43-56Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FMB.10.155
Keywords
bacteremia; epidemiology; Infective endocarditis; MRSA; Staphylococcus aureus; treatment
Categories
Funding
- The Danish Heart Foundation [08-10-68-A2155-B778-22512]
- [R01-AI068804]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068804] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Staphylococcus aureus bacteremia (SAB) is an urgent medical problem due to its growing frequency and its poor associated outcome. As healthcare delivery increasingly involves invasive procedures and implantable devices, the number of patients at risk for SAB and its complications is likely to grow. Compounding this problem is the growing prevalence of methicillin-resistant S. aureus (MRSA) and the dwindling efficacy of vancomycin, long the treatment of choice for this pathogen. Despite the recent availability of several new antibiotics for S. aureus, new strategies for treatment and prevention are required for this serious, common cause of human infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available